Manguso F, Balzano A
Gastroenterology Unit, A. Cardarelli Hospital, Naples, Italy.
Aliment Pharmacol Ther. 2007 Jul 1;26(1):21-9. doi: 10.1111/j.1365-2036.2007.03349.x.
Beclomethasone dipropionate (BDP) is a second-generation steroid with topical effects and minimal systemic activity for patients with ulcerative colitis (UC).
To review all available literature to assess the efficacy of enema/foam BDP compared with enema/foam 5-aminosalicylic acid (5-ASA) in the control of left-sided mild-moderate UC.
We selected randomized controlled trials of enema/foam BDP compared with enema/foam 5-ASA treatment in patients with UC. Two reviewers assessed trial quality and extracted data independently.
Four trials involving 428 UC patients, 209 treated with 5-ASA (1-4 g o.d.) and 219 with BDP (3 mg o.d.), were included. Intention-to-treat analysis showed that 5-ASA induced improvement/remission of UC in 146 (69.9%) patients, while BDP in 143 (65.3%). The test for heterogeneity (Cochran Q) was not significant and Mantel-Haenszel pooled estimate of odds ratio was 1.23 (95% CI = 0.82-1.85). The results did not change when analysis was performed on a per-protocol basis.
The randomized controlled trials identified in this review showed that rectal BDP has equal effect as 5-ASA to control symptoms in UC.
丙酸倍氯米松(BDP)是一种第二代类固醇药物,对溃疡性结肠炎(UC)患者具有局部作用且全身活性极小。
回顾所有可用文献,以评估BDP灌肠剂/泡沫剂与5-氨基水杨酸(5-ASA)灌肠剂/泡沫剂相比,在控制左侧轻至中度UC方面的疗效。
我们选择了比较BDP灌肠剂/泡沫剂与5-ASA灌肠剂/泡沫剂治疗UC患者的随机对照试验。两名研究者独立评估试验质量并提取数据。
纳入了四项试验,共428例UC患者,其中209例接受5-ASA治疗(每日1-4克),219例接受BDP治疗(每日3毫克)。意向性分析显示,5-ASA使146例(69.9%)患者的UC病情改善/缓解,而BDP使143例(65.3%)患者病情改善/缓解。异质性检验( Cochr an Q)无显著性差异,Mantel-Haenszel合并比值比估计值为1.23(95%CI = 0.82-1.85)。按符合方案分析时结果未改变。
本综述中确定的随机对照试验表明,直肠用BDP在控制UC症状方面与5-ASA效果相当。